Jiangsu Lianhuan Pharmaceutical Co., Ltd.

XSSC:600513 Stock Report

Market Cap: CN¥3.0b

Jiangsu Lianhuan Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Jiangsu Lianhuan Pharmaceutical has been growing earnings at an average annual rate of 11.3%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13.6% per year. Jiangsu Lianhuan Pharmaceutical's return on equity is 10%, and it has net margins of 5.9%.

Key information

11.3%

Earnings growth rate

11.0%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate13.6%
Return on equity10.0%
Net Margin5.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jiangsu Lianhuan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSSC:600513 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,335139798157
30 Jun 242,346136776166
31 Mar 242,251136744140
31 Dec 232,174135714132
30 Sep 232,026131722103
30 Jun 232,01313773997
31 Mar 232,00214273795
31 Dec 221,95514172992
30 Sep 221,88813271086
30 Jun 221,78313067671
31 Mar 221,71812466467
31 Dec 211,64611964466
30 Sep 211,59110960252
30 Jun 211,52911261049
31 Mar 211,42610956147
31 Dec 201,38610353544
30 Sep 201,3669752752
30 Jun 201,3528352851
31 Mar 201,3378257648
31 Dec 191,2908060947
30 Sep 191,1837962143
30 Jun 191,1107662242
31 Mar 191,0407458639
31 Dec 181,0197456438
30 Sep 189367751421
30 Jun 188577445232
31 Mar 187827341022
31 Dec 176897136220
30 Sep 176146730420
30 Jun 17590692910
31 Mar 17580632760
31 Dec 16605632750
30 Sep 16615582880
30 Jun 16625562880
31 Mar 16628512940
31 Dec 15642503000
30 Sep 15652482980
30 Jun 15661462970
31 Mar 15673452890
31 Dec 14669442830
30 Sep 14672442650
30 Jun 14673422570
31 Mar 14647412440
31 Dec 13623382340

Quality Earnings: 600513 has high quality earnings.

Growing Profit Margin: 600513's current net profit margins (5.9%) are lower than last year (6.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 600513's earnings have grown by 11.3% per year over the past 5 years.

Accelerating Growth: 600513's earnings growth over the past year (6.1%) is below its 5-year average (11.3% per year).

Earnings vs Industry: 600513 earnings growth over the past year (6.1%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 600513's Return on Equity (10%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:47
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Lianhuan Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution